Invesco Nasdaq Biotechnology ETF (IBBQ)

$23.15 +0.14 (0.61%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 3,692
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capita...

BioRich
BioRich Jun. 15 at 1:18 PM
$CAPR Jumping in with two feet at PPMD. For good reason as they look to take over the DMD space from $SRPT. Quite the exciting time. Disclosure, I absolutely love Sarepta and what they've done for these young men. Doug Ingram is about as savvy as it gets as a CEO (or at least was when I was following them closely). $SRPT is the reason I joined @Stocktwits and the reason I came up with this silly user name. That being said, it appears there's a changing of the guard and $CAPR is getting hot at the right time for the takeover as $SRPT faces future challenges. Again, thank you $SRPT, but it's time to move on to $CAPR and support them to the tilt to help these young men. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $IBB $IBBQ
1 · Reply
StocktwitsNews
StocktwitsNews Jun. 12 at 3:21 PM
Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’ $MESO $APIE $IBBQ https://stocktwits.com/news/equity/markets/mesoblast-gives-positive-update-about-potential-fda-application-for-revascor/chlgT5lRb6z
0 · Reply
BioRich
BioRich Jun. 11 at 2:16 PM
$CAPR I thought the boat was loaded but a manipulation dip on great news...yup, I averaged up and stacking the decks as much as this boat will hold. Truly a tremendous buy opportunity here. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $IBB $IBBQ
2 · Reply
BioRich
BioRich Jun. 7 at 2:33 PM
$XBI $ALT This summarizes the ALT Board in a nutshell. It reveals factual information about the company/stock and because it doesn't pump Best-in-Class MASH, Partnership, or Buyout, it gets no fanfare. Might be the final straw for some on-the-fence Bulls that are sick of putting lipstick on this ugly pig. The inconsistencies in this company create more drama than the Kardashian's and are about as close to reality as them. $ALT is a Wall Street manipulation pet. Data and science have become relatively secondary here. Easiest example: ALT is on the horizon of what many on this board consider to be Best-In-Class MASH P2b trial data (which many think, by their posts, will hit multiples in SP upon data drop) and Short interest is relatively unchanged over the last month ~30%. Don't listen to me, listen to Wall Street. They know too. Follow/Subscribe for more suggestions and perspective. That's how we learn. Let's make some money. Cheers! $IBB $IBBQ $RUT
0 · Reply
KimberleyAnn
KimberleyAnn Jun. 7 at 8:11 AM
$PYPD $IBB $IBBQ
0 · Reply
BioRich
BioRich Jun. 4 at 8:35 PM
$ALT @VisionGT Based on what you wrote, one of 2 things are true: 1) Dr. Harris lied, and as such, has committed an SEC Violation 2) The "delay" is because they are still re-reading the biopsies. These are your two realities, and neither involve anything related to PS or BO. And again, as I've shared with this group before, $ALT is not "actively engaged" in "direct discussions" with ANY potential suitor at this point. Doesn't mean there weren't discussions in the past (Betaville rumor time), but there are none that are "active". I know you won't take my word for it so please contact Investor Relations. Remember, I share truth from reliable sources. Follow/Subscribe for more suggestions and perspective. Cheers! $XBI $VKTX $IBB $IBBQ
1 · Reply
BioRich
BioRich Jun. 4 at 2:46 PM
$XBI $ALT Just a friendly reminder after $ALT again confirmed today on their Jefferies call that Obesity, as an indication, is done that this puts Jefferies PT @ $2.39/share. This is likely why ALT is not going "to the moon" after the call this morning. Reality > Hope Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we learn. Let's make some money. Cheers! ~BioRich Capital $IBB $IBBQ $BTK
2 · Reply
BioRich
BioRich Jun. 3 at 5:49 PM
$CADL "As a physician, I like being able to tell patience they have a 30-40% chance of improved survival by taking this treatment." ~KOL on $CADL Call Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital $XBI $IBB $IBBQ $JNJ
1 · Reply
BioRich
BioRich Jun. 3 at 2:00 PM
$ALT For those excited about Jeffries tomorrow, here's your cheat sheet for MASH P2b success probability put out by Jeffries already. While the chart has confused many on this board, Jeffries projects there's an ~50% likelihood ALT will NOT hit stat significance on both primary endpoints. Have fun with this folks. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we learn. Let's make some money. Cheers! $XBI $IBB $IBBQ
4 · Reply
BioRich
BioRich Jun. 3 at 1:45 PM
$ALT Nothing but a pump attempt here. No merit. Be prepared to be disappointed. To your points: 1. Misleading - DB lock confirmation is unavailable so making assumptions here is loose. (As a side note, ALT is master class at word play. Imminent to them could be ANY time). 2. Stretch - You're making conclusions based on hope and trying to paint a picture that's not there. Yes, ALT does a lot of stuff that doesn't make sense and endlessly disappoints SHs so Jeffries is likely no different. 3. Misleading - Doan post is a nothing burger. Short interest is confident in negative SP movement (aka, bad data). 4. Stretch - Opportunity is only as good as having product. Additionally, confirming the company is a POS doesn't mean they can flip a switch and become appealing. Final Take - They don't have data yet. They will stick to EoJ. Nothing but hope speculation here. Appreciate the try, but I'm confident there's ZERO chance of data at Jeffries. $XBI $IBB $IBBQ
1 · Reply
Latest News on IBBQ
Healthcare Sector Checkup As U.S. Looks To Change Regulations

May 30, 2025, 3:30 PM EDT - 25 days ago

Healthcare Sector Checkup As U.S. Looks To Change Regulations

AGNG ARKG BBC BBH BBP BIB BIS

Seeking Stocks With Vitality In The Volatile Healthcare Sector

Feb 25, 2025, 11:06 AM EST - 4 months ago

Seeking Stocks With Vitality In The Volatile Healthcare Sector

IBB XLV AGNG ARKG BBC BBH BBP

IBBQ: This Low-Cost Biotech ETF Comes With Unique Risks

Sep 21, 2024, 11:27 PM EDT - 9 months ago

IBBQ: This Low-Cost Biotech ETF Comes With Unique Risks

Can Health Care Stocks Outperform Again In 2023?

Jan 11, 2023, 6:09 PM EST - 2 years ago

Can Health Care Stocks Outperform Again In 2023?

AGNG ARKG BBC BBH BBP BMED CNCR

IBBQ: Healthcare Dashboard For December

Dec 18, 2022, 5:00 AM EST - 2 years ago

IBBQ: Healthcare Dashboard For December

Why Now Could Be The Time To Consider Neuroscience Investments

Aug 27, 2022, 4:45 AM EDT - 3 years ago

Why Now Could Be The Time To Consider Neuroscience Investments

ARKG BBH BIB FBT GNOM HELX IBB

BioRich
BioRich Jun. 15 at 1:18 PM
$CAPR Jumping in with two feet at PPMD. For good reason as they look to take over the DMD space from $SRPT. Quite the exciting time. Disclosure, I absolutely love Sarepta and what they've done for these young men. Doug Ingram is about as savvy as it gets as a CEO (or at least was when I was following them closely). $SRPT is the reason I joined @Stocktwits and the reason I came up with this silly user name. That being said, it appears there's a changing of the guard and $CAPR is getting hot at the right time for the takeover as $SRPT faces future challenges. Again, thank you $SRPT, but it's time to move on to $CAPR and support them to the tilt to help these young men. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $IBB $IBBQ
1 · Reply
StocktwitsNews
StocktwitsNews Jun. 12 at 3:21 PM
Mesoblast Gives Positive Update About Potential FDA Application For Heart Failure Therapy: Retail Sees ‘Inflection Point’ $MESO $APIE $IBBQ https://stocktwits.com/news/equity/markets/mesoblast-gives-positive-update-about-potential-fda-application-for-revascor/chlgT5lRb6z
0 · Reply
BioRich
BioRich Jun. 11 at 2:16 PM
$CAPR I thought the boat was loaded but a manipulation dip on great news...yup, I averaged up and stacking the decks as much as this boat will hold. Truly a tremendous buy opportunity here. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! $XBI $IBB $IBBQ
2 · Reply
BioRich
BioRich Jun. 7 at 2:33 PM
$XBI $ALT This summarizes the ALT Board in a nutshell. It reveals factual information about the company/stock and because it doesn't pump Best-in-Class MASH, Partnership, or Buyout, it gets no fanfare. Might be the final straw for some on-the-fence Bulls that are sick of putting lipstick on this ugly pig. The inconsistencies in this company create more drama than the Kardashian's and are about as close to reality as them. $ALT is a Wall Street manipulation pet. Data and science have become relatively secondary here. Easiest example: ALT is on the horizon of what many on this board consider to be Best-In-Class MASH P2b trial data (which many think, by their posts, will hit multiples in SP upon data drop) and Short interest is relatively unchanged over the last month ~30%. Don't listen to me, listen to Wall Street. They know too. Follow/Subscribe for more suggestions and perspective. That's how we learn. Let's make some money. Cheers! $IBB $IBBQ $RUT
0 · Reply
KimberleyAnn
KimberleyAnn Jun. 7 at 8:11 AM
$PYPD $IBB $IBBQ
0 · Reply
BioRich
BioRich Jun. 4 at 8:35 PM
$ALT @VisionGT Based on what you wrote, one of 2 things are true: 1) Dr. Harris lied, and as such, has committed an SEC Violation 2) The "delay" is because they are still re-reading the biopsies. These are your two realities, and neither involve anything related to PS or BO. And again, as I've shared with this group before, $ALT is not "actively engaged" in "direct discussions" with ANY potential suitor at this point. Doesn't mean there weren't discussions in the past (Betaville rumor time), but there are none that are "active". I know you won't take my word for it so please contact Investor Relations. Remember, I share truth from reliable sources. Follow/Subscribe for more suggestions and perspective. Cheers! $XBI $VKTX $IBB $IBBQ
1 · Reply
BioRich
BioRich Jun. 4 at 2:46 PM
$XBI $ALT Just a friendly reminder after $ALT again confirmed today on their Jefferies call that Obesity, as an indication, is done that this puts Jefferies PT @ $2.39/share. This is likely why ALT is not going "to the moon" after the call this morning. Reality > Hope Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we learn. Let's make some money. Cheers! ~BioRich Capital $IBB $IBBQ $BTK
2 · Reply
BioRich
BioRich Jun. 3 at 5:49 PM
$CADL "As a physician, I like being able to tell patience they have a 30-40% chance of improved survival by taking this treatment." ~KOL on $CADL Call Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital $XBI $IBB $IBBQ $JNJ
1 · Reply
BioRich
BioRich Jun. 3 at 2:00 PM
$ALT For those excited about Jeffries tomorrow, here's your cheat sheet for MASH P2b success probability put out by Jeffries already. While the chart has confused many on this board, Jeffries projects there's an ~50% likelihood ALT will NOT hit stat significance on both primary endpoints. Have fun with this folks. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we learn. Let's make some money. Cheers! $XBI $IBB $IBBQ
4 · Reply
BioRich
BioRich Jun. 3 at 1:45 PM
$ALT Nothing but a pump attempt here. No merit. Be prepared to be disappointed. To your points: 1. Misleading - DB lock confirmation is unavailable so making assumptions here is loose. (As a side note, ALT is master class at word play. Imminent to them could be ANY time). 2. Stretch - You're making conclusions based on hope and trying to paint a picture that's not there. Yes, ALT does a lot of stuff that doesn't make sense and endlessly disappoints SHs so Jeffries is likely no different. 3. Misleading - Doan post is a nothing burger. Short interest is confident in negative SP movement (aka, bad data). 4. Stretch - Opportunity is only as good as having product. Additionally, confirming the company is a POS doesn't mean they can flip a switch and become appealing. Final Take - They don't have data yet. They will stick to EoJ. Nothing but hope speculation here. Appreciate the try, but I'm confident there's ZERO chance of data at Jeffries. $XBI $IBB $IBBQ
1 · Reply
BioRich
BioRich Jun. 3 at 12:50 PM
$ALT In case y'all missed it, the Sara Doan picture is nothing. ALT has a lot of remote workers and this is their monthly on-site. If took more than 2 seconds, they would know this. Desperation is Dangerous. And for those that don't realize it, each time one of these speculations gets pumped and then unfounded, it results in a net negative for the company. Wall Street is tired of the games but Shorts love it. Cheers! $XBI $IBB $IBBQ
1 · Reply
BioRich
BioRich May. 30 at 9:29 PM
$ALT Just a friendly reminder. Nothing has changed other than frustration levels with this turd increasing and Share Price decreasing. Y'all don't have to listen...but you'll wish you did. BioRich Capital Re-Iterates it's "Strong Sell" rating for $ALT and maintains a 1-year PT of $2.69. This PT can hit by end of June if MASH P2b data disappoints. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital. $XBI $IBB $IBBQ
1 · Reply
BioRich
BioRich May. 30 at 3:59 PM
$ALT @Bull65 is just another @jacksparo burner account while Jack is suspended. On a more pertinent note, guy has great information to support why $ALT should be poised for a short squeeze. Unfortunately, the short squeeze set-up has been there for a year, with many "events" that could have squeezed it, and Shorts aren't worried. That's pretty telling. Thanks for the info Jack, but you just added fuel to the very strong Bear Case for $ALT. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we learn. Let's make some money. Cheers! ~BioRich Capital $XBI $IBB $IBBQ
0 · Reply
BioRich
BioRich May. 29 at 8:49 PM
$XBI Imagine what the Short Interest would be on $ALT if it was as easy to Short as it was to Buy Long. I think we'd be at about 70% at this point. $IBB $IBBQ
1 · Reply
BioRich
BioRich May. 29 at 4:07 PM
$ALT This right here is EXACTLY why it's impossible to reason with someone pumping ALT. This wrongfully combines data from different trials and different phases for Altimmune to make it seem like a mirracle drug. It is anything but. The Weight Loss claims come from the Obesity trial, which is currently shelved, that had its data HEAVILY aided by Diet and Exercise Lifestyle Interventions. What the folks from the $ALT board don't realize is that when the pump Gargage like this, it clearly shows that $VKTX is a significantly better choice and Altimmune is all but dead. Thanks for posting @Designed2Gain. Another example of an ALT pumper that gets embarrassed when non-pumpers eyes see the Gargage you're pushing. Do better. $XBI $IBB $IBBQ
2 · Reply
BioRich
BioRich May. 29 at 2:11 AM
$ALT @Space_Dust, while I thought we had put this to bed, you keep bringing it up. MASHResInd is nothing more than a prediction using an unvalidated machine learning algorithm. Without invoking the BioRich Confidence Index (BCI), the MASHResInd is nothing more than a number. In summary, absolutely NO claims regarding ALT's MASH Resolution and/or Fibrosis can legitimately be made using the MASHResInd. Follow/Subscribe for more suggestions and perspective. Cheers! $XBI $IBB $IBBQ $VKTX
2 · Reply
BioRich
BioRich May. 27 at 3:43 AM
$ALT Gonna be a lot of restless nights this evening. Hope everyone gets some rest. BIG DAY tomorrow! May start with a PR pre-market? And does anyone have the links to the webcasts for $ALT's meetings tomorrow and Wednesday? Most importantly, those lost will never be forgotten. Happy Memorial Day. $XBI $NASDAQ $IBB $IBBQ
2 · Reply
BioRich
BioRich May. 26 at 4:55 PM
$XBI $ALT While I appreciate optimism, I appreciate realism more. The most glaring flaw here is acknowledgement that Obesity is dead and/or MASH data isn't good. Not leaning towards what MASH data will look like, or how the market responds, simply pointing out that there's a lot of effort selling the idea of Buyout when this is the least likely scenario by several magnitude (simple math, no relation to the company specifically). This level of effort is great for likes and raising optimism, but if Bulls wanted to share realistic and useful information, they should organically look at what "success" looks like with upcoming MASH data and expectations on share price utilizing all resources. That wouldn't get as many likes and fist pumps though, so here we are. Classic lottery ticket scenario. Cheers! $NASDAQ $IBB $IBBQ
5 · Reply
BioRich
BioRich May. 23 at 2:51 PM
$MIST HUGE Catalysts on the horizon. RealPTs: 1-month - $2.50 (Successful Inspection) 3-month - $4.00 (Successful FDA Meeting) 6-month - $8.00 (FDA Approval) 24-month - $18.00 (FDA Approval and Revenue) Obviously, Buyout/Partnership is always a potential, but can't be predicted. Very attractive target though. Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we learn. Let's make some money. Cheers! $XBI $IBB $IBBQ $PFE
2 · Reply
BioRich
BioRich May. 23 at 1:51 PM
$XBI $ALT $IBB $IBBQ Altimmune (ALT) sort of screwed themselves by pumping lofty "predictive" values at EASL that were based on an unvetted, unvalidated machine learning algorithm that showed MASH resolution >90%. From my perspective, $ALT inadvertently raised their own bar of what success looks like and will be penalized significantly if they don't meet the MASHResInd numbers. Thoughts? Follow/Subscribe for more suggestions and perspective. Would love to hear yours, too. That's how we learn. Let's make some money. Cheers!
2 · Reply
BioRich
BioRich May. 23 at 1:32 PM
$ALT $XBI $IBB $IBBQ Friendly reminder regarding Altimmune's recent financial moves that raise significant questions regarding MASH P2b data. This is NOT a bash, these are the financial facts regarding ALT borrowing and dilution year to date.
0 · Reply
BioRich
BioRich May. 23 at 12:49 PM
$ALT My money is on ALT announcing they are formally discontinuing the Obesity Program. Garg's recent addressing of the Obesity Program, as an indication, in the recent fireside chat, likely forced ALT's hands to make a material announcement (for SEC reasons). The quick nature of the meeting supports the need to make a formal announcement. While many will dispute formally killing the Obesity Program is irrelevant, it is very relevant as the Program greatly affects analyst price targets. This is HUGE, possibly a large SP impact than MASH P2b data. As has been mentioned numerous times before, $ALT Price Targets by analysts are HEAVILY weighted for Obesity, as an indication. Much heavier than MASH and the remainder of $ALT's pipeline. As posted before, in the Jeffries best case scenario, $ALT's PT would suggest $2.39/share without the Obesity Program. THIS is what would required 2 days of announcements, discussions and meetings with analysts covering ALT. Cheers! $XBI $IBB $IBBQ
0 · Reply